A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
TG Therapeutics, Inc.

Protocol Number
UTX-TGR-205

To Learn More Call
201-510-0910